Glaxosmithkline Share News (GSK)

GlaxoSmithKline starts phase III study of asthma treatment

(ShareCast News) - GlaxoSmithKline has announced the start of a phase III study of its once-daily triple combination therapy fluticasone furoate/umeclidinium/vilanterol as a treatment for patients with asthma. The study, which will be conducted in partnership with Innoviva Inc, will compare the trea

Tuesday broker round-up

(ShareCast News) - British Land: Barclays reiterates overweight with a target price of 740p. GlaxoSmithKline: UBS reiterates neutral, 1600p target. Reckitt Benckiser: Jefferies reiterates buy with a 7750p target. GB Group: Berenberg reiterates buy with a 340p target. Great Portland Estates: Barcl

BUZZ-European Pharma: UBS shuffles recommendations

** UBS analysts say investors in healthcare stocks should seek exposure to oncology and new expensive drugs which displace older expensive drugs; avoid therapy areas at risk of becoming crowded and new drugs with high budget impact ** Brokerage double upgrades to "buy" from "sell" Novo Nord

BROKER RATINGS SUMMARY: Credit Suisse Raises Rio Tinto And Cuts BHP

GSK insider Waterhouse to head drugmaker's HIV unit ViiV

LONDON, Dec 5 (Reuters) - GlaxoSmithKline said on Monday that Dominique Limet would step down at the end of March 2017 as head of the drugmaker's majority-owned HIV business ViiV Healthcare, to be replaced by GSK insider Deborah Waterhouse. Waterhouse, currently in charge of primary care wi

TOP NEWS: Glaxo's Relvar Ellipta Approved For COPD In Japan

Japan approves GSK's bronchitis and emphysema drug

(ShareCast News) - The Japanese government has approved GlaxoSmithKilne and Nasdaq-listed Innoviva's drug which treats chronic bronchitis and pulmonary emphysema. Japan's Ministry of Health, Labour and Welfare approved the use of Relvar, which relieves symptoms of chronic obstructive pulmonary disea

Thursday newspaper round-up: Pensions, Fitbit, Glaxo, Logica

(ShareCast News) - Labour has vowed to protect pensioner benefits, free bus passes and the winter fuel payment until 2025 in an attempt to dent the overwhelming support for the Conservative party among older voters. The £3bn-a-year commitment comes just one week after Philip Hammond, the chancellor,

GSK biotech asthma drug wins UK approval after extra price cut

LONDON, Dec 1 (Reuters) - GlaxoSmithKline's new injectable asthma drug Nucala has been recommended for use in Britain's state-run health service in the most severe patients, after the drugmaker provided further analyses on its use and made an additional price cut. The National Institute for

Injections, implants tested as new weapons to prevent HIV

* GSK to start large trials testing protective injection * Under-skin implants seen as promising long-term option * New HIV cases still running at 1.9 million annually By Ben Hirschler LONDON, Nov 29 (Reuters) - Scientists are taking the battle to prevent HIV to the next l

GlaxoSmithKline seeks European approval for shingles vaccine

(ShareCast News) - GlaxoSmithKline announced the regulatory submission of a marketing authorisation application to the European Medicines Agency for approval of its candidate shingles vaccine, Shingrix. The phase III clinical trial of the vaccine - for the prevention of shingles in people over 50 an

BUZZ-AstraZeneca: boosted by Liberum upgrade as Healthcare rallies

** AstraZeneca +1%, second-top riser on FTSE 100 in volume ** Liberum upgrades to "buy" v "hold" - with stock down 8 pct YTD, trading around 5-mth lows, risk/reward going into a rich seam of catalysts is now strongly to the upside ** Four major immuno-oncology readouts in 2017 (incl.

GlaxoSmithKline starts Phase III studies of daprodustat for anaemia

(ShareCast News) - GlaxoSmithKline has started a phase III development programme to investigate daprodustat for anaemia associated with chronic kidney disease. The programme includes two studies evaluating the safety and efficacy of daprodustat compared to recombinant human erythropoietin. ASCEND-D

Alzheimer's setback prompts rethink of Lilly, Biogen stock outlooks

By Lewis Krauskopf NEW YORK, Nov 23 (Reuters) - Eli Lilly & Co's massive setback for its experimental Alzheimer's disease treatment on Wednesday sent investors scrambling to re-evaluate shares of the U.S. drugmaker and those of companies making competing therapies, including biotech stalwa

GSK EGPA treatment meets endpoints in phase 3 study

(ShareCast News) - GlaxoSmithKline said on Wednesday that both co-primary endpoints and all secondary endpoints were met in a "pivotal" phase III study investigating the efficacy and safety of it smepolizumab treatment in patients with relapsing and refractory Eosinophilic Granulomatosis with Polyan